Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Change in Receivables (2018 - 2025)

Historic Change in Receivables for Aclaris Therapeutics (ACRS) over the last 8 years, with Q2 2025 value amounting to -$56000.0.

  • Aclaris Therapeutics' Change in Receivables fell 1666.67% to -$56000.0 in Q2 2025 from the same period last year, while for Jun 2025 it was -$131000.0, marking a year-over-year decrease of 2358.49%. This contributed to the annual value of $20000.0 for FY2024, which is 11075.27% up from last year.
  • Per Aclaris Therapeutics' latest filing, its Change in Receivables stood at -$56000.0 for Q2 2025, which was down 1666.67% from -$68000.0 recorded in Q1 2025.
  • In the past 5 years, Aclaris Therapeutics' Change in Receivables registered a high of $202000.0 during Q1 2023, and its lowest value of -$255000.0 during Q2 2023.
  • Moreover, its 5-year median value for Change in Receivables was -$44000.0 (2022), whereas its average is -$32111.1.
  • Over the last 5 years, Aclaris Therapeutics' Change in Receivables had its largest YoY gain of 192000.0% in 2023, and its largest YoY loss of 647500.0% in 2023.
  • Over the past 5 years, Aclaris Therapeutics' Change in Receivables (Quarter) stood at -$188000.0 in 2021, then soared by 39.89% to -$113000.0 in 2022, then surged by 57.52% to -$48000.0 in 2023, then soared by 47.92% to -$25000.0 in 2024, then tumbled by 124.0% to -$56000.0 in 2025.
  • Its last three reported values are -$56000.0 in Q2 2025, -$68000.0 for Q1 2025, and -$25000.0 during Q4 2024.